Back to Clinical Trials

Brief Title: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

INTRODUCTION

  • Org Study ID: 00-014
  • Secondary ID: N/A
  • NTC ID: NCT00579514
  • Sponsor: Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center

BRIEF SUMMARY

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

DETAILED DESCRIPTION

To establish significant correlations between genetic polymorphisms and cancer, a largescale, systematic comparison of genetic alterations utilizing a case-control methodology is proposed. To date, such studies have been limited due to the large number of samples necessary for obtaining statistical significance, and the lack of rapid and accurate methods to screen for genetic polymorphisms. We propose to utilize an anonymized design to obtain DNA from residual material from routine diagnostic blood tests, to link these samples to a limited set of clinical variables, and to test for the frequency of candidate low-penetrance cancer susceptibility alleles. These data will be combined with similar data from a control group of age- and ethnically-matched volunteers for a related cohort study to be conducted separately. Polymorphisms to be screened for include those involving the genes PTEN, APC, TGF βR-I, BLM, CHK2, a p85 phosphoprotein, ATM, ER, PR, MCP-1, MPIF, CCR2/5, CCR3, and SULT1A1. Cancers to be included are breast, bladder, kidney,colon, testicular, lung, prostate, ovarian, lymphoid neoplasms, and head and neck carcinomas. Genes with SNPs known to be relevant for either the development or treatment of lymphoid malignancies will also be targeted. Specifically, candidate genes will be selected from 1) cytokine signaling, 2) DNA repair, and 3) apoptosis regulatory pathways.

  • Overall Status
    Recruiting
  • Start Date
    March 2000
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: To collect anonymized germline DNA from patients with breast, bladder, kidney, lung, colon, testicular, prostate, lymphoid, ovarian or head and neck cancers, as well as patients with multiple primary cancers, from select New York City ethnic groups.

Primary Outcome 1 - Timeframe: 20 years

CONDITION

  • Breast Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Colon Cancer
  • Prostate Cancer
  • Lung Cancer
  • Ovarian Cancer

ELIGIBILITY

Inclusion Criteria:
Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney, testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic blood sample as either an inpatient or outpatient at MSKCC.

- All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites.

- Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any type.

- Samples ascertained as part of protocol 98-024A(1) are also eligible for ascertainment in this study.
Exclusion Criteria:
MSKCC patients without a histologic diagnosis of cancer of the breast, bladder, kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma) will not be eligible for the AMDeC sponsored component of the study.

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Kenneth Offit, MD

Role: Principal Investigator

Affiliation: Memorial Sloan Kettering Cancer Center

Overall Contact

Name: Kenneth Offit, MD

Phone: 646-888-4067

Email: N/A

LOCATION

Facility Status Contact
Facility: Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Status: Recruiting Contact: Contact
Kenneth Offit, MD
646-888-4067